Preferred Label : NY-ESO-1 Peptides/Threitolceramide-6-loaded Nanoparticles PORT-3;
NCIt synonyms : Nanoparticles PORT-3; NY-ESO-1 Peptides/ThrCer6-loaded Nanoparticles PORT-3; NY-ESO-1 Peptides/Threitolceramide-6-encapsulating Nanoparticles PORT-3; PLGA Nanoparticles Loaded with NY-ESO-1 Peptides/IMM60;
NCIt definition : An immunomodulating agent and nanovaccine composed of the invariant natural killer
T cell (iNKT) agonist, dendritic cell (DC) transactivator, and an alpha-galactosylceramide
(a-GalCer) analog threitolceramide-6 (ThrCer6, IMM60) and immunogenic peptides derived
from the tumor-associated antigen (TAA) New York Esophageal Squamous Cell Carcinoma-1
(NY-ESO-1) encapsulated within poly(lactic-co-glycolic acid) (PLGA) nanoparticles,
with potential immunomodulating and antineoplastic activities. Upon administration
of NY-ESO-1 peptides/ThrCer6-loaded nanoparticles PORT-3, ThrCer6 targets and binds
to the T-cell receptor on iNKTs, thereby activating the iNKTs. The activated iNKTs
activate DCs, resulting in the secretion of a large amount of pro-inflammatory cytokines.
The NY-ESO-1 peptides are processed and presented by DCs. Altogether, this induces
antigen-specific CD4 and CD8 T cell, and B cell responses, and leads to the induction
of a cytotoxic T-lymphocyte (CTL)-mediated immune response against NY-ESO-1-expressing
tumor cells. Encapsulating antigens and adjuvants together within the same biodegradable
polymeric nanoparticle can enhance T cell responses. NY-ESO-1 is a cancer-testis antigen
normally expressed in testicular germ cells and trophoblasts of the placenta and overexpressed
in a variety of cancers.;
Molecule name : PORT 3; PORT-3;
NCI Metathesaurus CUI : CL1662180;
Origin ID : C179607;
UMLS CUI : C5555811;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
